DNA-targeted radioimmunotherapy

DNA靶向放射免疫治疗

• 批准号: nhmrc : 209125
• 负责人: Prof Jonathan White
• 金额: $ 26.12万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2002
• 资助国家: 澳大利亚
• 起止时间: 2002-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dna-targeted-radioimmunotherapy/101360
• 关键词: DNA; targeted; radioimmunotherapy

Radioimmunotherapy is an experimental method of cancer treatment, involving the use of radioactive isotopes, which are targeted to tumour cells using specific molecules as carriers. These carriers are known as anti-tumour antibodies, and they bind specifically to tumour cells. Recent advances in molecular biology and in the understanding of the nature of tumour cells has resulted in the development of improved anti-tumour antibodies, and such improvements can be expected to continue. However, this project is concerned not with the tumour targeting aspect of radioimmunotherapy, but rather with the payload or cytotoxic mechanism, in which the radiation damage is focused on the DNA of the cell. In summary, the project explores a new approach in cancer radioimmunotherapy. This approach will be evaluated firstly in cultures of tumour cells and then in mice bearing transplanted tumours. If successful this project will result in the development of a new cell kill technology that can be combined with different anti-tumour antibodies.

放射免疫疗法是一种实验性癌症治疗方法，涉及使用放射性同位素，其使用特定分子作为载体靶向肿瘤细胞。这些载体被称为抗肿瘤抗体，它们特异性地与肿瘤细胞结合。分子生物学和对肿瘤细胞性质的理解的最新进展已经导致了改进的抗肿瘤抗体的开发，并且可以预期这种改进将继续下去。然而，该项目并不关注放射免疫疗法的肿瘤靶向方面，而是关注有效载荷或细胞毒性机制，其中辐射损伤集中在细胞的DNA上。总之，该项目探索了癌症放射免疫治疗的新方法。这种方法将首先在肿瘤细胞培养物中进行评估，然后在携带移植肿瘤的小鼠中进行评估。如果成功，该项目将导致开发一种新的细胞杀伤技术，可以与不同的抗肿瘤抗体结合。